Best Stocks to Invest in Now. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands ...

The global satellite IoT subscriber base grew to surpass 5.1 million in 2023. The number of satellite IoT subscribers is predicted to increase at a compound annual growth rate (CAGR) of 39.2 per cent ...

A new report from the World Travel & Tourism Council (WTTC) has revealed that business travel is set to surpass pre-pandemic ... remaining 5.4% behind. But as business leaders re-emphasised ...

Four days after a compounding industry group filed a lawsuit against the FDA for removing Eli Lilly’s tirzepatide products ... the company said it would spend $4.5 billion to build an R&D ...

Among other things, the investment will help explore new ways of delivering health services to people living with obesity, and include a five-year trial of the company’s drug tirzepatide ...

Pharmacists can continue making compounded versions of generic tirzepatide, the active ingredient in popular medications Mounjaro and Zepbound, the Food and Drug Administration said in a recent ...

Pharmacists may continue making compounded versions of the weight-loss medication tirzepatide while the U.S. Food and Drug ...

The UK Government, devolved nations and NHS England have signed a collaboration agreement with Lilly, the pharmaceutical giant behind weight loss medication tirzepatide. The Government said the ...

Mounjaro is a weekly injectable pen used for weight loss. It contains tirzepatide which works by regulating blood sugar and energy balance levels, helping to reduce appetite and prevent cravings.

Tirzepatide is sold as Mounjaro for diabetes and Zepbound for obesity. In a statement to The Hill, a spokesperson for Lilly said all doses of Mounjaro and Zepbound are available and reiterated the ...